| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 121.09 | 1284 |
| Intrinsic value (DCF) | 6.62 | -24 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 1.94 | -78 |
MyHealthChecked PLC (LSE: MHC) is a UK-based healthcare company specializing in at-home diagnostic and wellness testing solutions. Headquartered in Cardiff, the company develops and commercializes innovative home healthcare products, including its flagship MyLotus testing strip, COVID-19 sample collection kits, and a range of DNA/RNA tests. Operating in the medical devices sector, MyHealthChecked caters to the growing demand for convenient, consumer-driven health monitoring tools. The company rebranded from Concepta PLC in December 2020 to reflect its strategic focus on digital health solutions. With a market capitalization of approximately £6.1 million, MyHealthChecked targets the expanding global home diagnostics market, which has seen accelerated growth due to increased health awareness and the COVID-19 pandemic. The company's product portfolio positions it at the intersection of healthcare technology and consumer wellness trends.
MyHealthChecked presents a high-risk, high-reward investment proposition in the rapidly evolving home diagnostics sector. The company's £10.98 million revenue in 2023 shows commercial traction, though its £159k net loss and negative EPS (-0.31p) raise concerns about profitability. A beta of 1.5 indicates higher volatility than the market. Positive operating cash flow (£724k) and strong cash position (£7.75 million) provide some financial flexibility, but the lack of dividends and minimal debt suggest the company is reinvesting for growth. Investment appeal hinges on the company's ability to scale its product line, capitalize on post-pandemic health testing trends, and achieve profitability in a competitive market. The stock may suit investors with higher risk tolerance seeking exposure to the digital health revolution.
MyHealthChecked operates in the crowded at-home diagnostic market, competing against both established medical device companies and digital health startups. The company's primary competitive advantage lies in its specialized focus on consumer-friendly testing solutions and its UK manufacturing base, which may provide supply chain advantages in its home market. However, its small scale (£10.98M revenue) leaves it vulnerable to larger competitors with greater R&D budgets and distribution networks. The MyLotus testing strip differentiates through its specific technology, but faces competition from more comprehensive testing platforms. MyHealthChecked's COVID-19 kits benefited from pandemic demand, but sustaining growth requires diversifying into other health testing categories. The company's challenge is to build brand recognition against better-funded rivals while navigating regulatory hurdles in multiple markets. Its cash position provides runway for product development, but the lack of profitability raises questions about long-term viability without significant scale-up or partnership opportunities.